IER5L silencing compromises tumor growth and decreases the capability of prostate cancer cells to form colonies in foci-formation assays as well as the anchorage-independent growth, while the population doubling rate in 2D unchallenged conditions remains unperturbed. Here, IER5L is linked to prostate cancer.